Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions,
Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...
Hosted on MSN13d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly approved drugs—and often declared them overpriced—companies in the indus | ...
Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...
Molecular Partners will present at TD Cowen and Leerink healthcare conferences and host a financial results call on March 7. Molecular Partners AG, a clinical-stage biotech company focused on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback